Shares of IPCA Laboratories Ltd. fell more than 3% on the NSE as investors brace for the company’s Q2 FY25 earnings results. As of 11:14 AM, the stock was trading 2.88% lower at ₹1,514.60.
Market expectations for IPCA Laboratories’ Q2 FY25 performance are as follows:
- Revenue: Projected at ₹2,340 crore, up from ₹2,034 crore in the same period last year.
- EBITDA: Expected to increase to ₹480 crore, compared to ₹321 crore in Q2 FY24.
- EBITDA Margin: Forecasted at 20.51%, a rise from the previous 15.78%.
- Net Profit: Anticipated to reach ₹266 crore, significantly up from ₹145 crore year-on-year.
The share price decline reflects cautious sentiment among investors, who are awaiting confirmation of the projected earnings growth, especially in profitability and margin improvement.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
